Corrigendum: Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition (Nature (2016) 537 (544-547) DOI: 10.1038/nature19353);Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition

Nature

Volumn 537, Issue 7621, 2016, Pages 544-547

  Sciacovelli, Marco ^a   Gonçalves, Emanuel ^b   Johnson, Timothy Isaac ^a   Zecchini, Vincent Roberto ^a   Da Costa, Ana Sofia Henriques ^a   Gaude, Edoardo ^a   Drubbel, Alizee Vercauteren ^a   Theobald, Sebastian Julian ^a   Abbo, Sandra Riekje ^a   Tran, Maxine Gia Binh ^c,i   Rajeeve, Vinothini ^d   Cardaci, Simone ^e   Foster, Sarah ^c   Yun, Haiyang ^f   Cutillas, Pedro ^d   Warren, Anne ^c   Gnanapragasam, Vincent ^c   Gottlieb, Eyal ^e   Franze, Kristian ^c   Huntly, Brian ^f   Maher, Eamonn Richard ^c,g   Maxwell, Patrick Henry ^f   Saez Rodriguez, Julio ^b,h   Frezza, Christian ^a   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g NIHR Cambridge Biomedical Research Centre   (United Kingdom)

^h RWTH AACHEN UNIVERSITY   (Germany)

ⁱ ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FUMARATE HYDRATASE; FUMARIC ACID; MICRORNA; MICRORNA 200; TRANSCRIPTION FACTOR; FUMARIC ACID DERIVATIVE; MIRN200 MICRORNA, HUMAN; TRANSCRIPTOME;

CANCER; CARBOXYLIC ACID; CELLS AND CELL COMPONENTS; CHEMICAL COMPOUND; ENZYME ACTIVITY; GENE EXPRESSION; METABOLITE; MUTATION; PHENOTYPE; PROTEIN; RODENT; TUMOR;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CLINICAL OUTCOME; CONTROLLED STUDY; DEMETHYLATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; KIDNEY CANCER; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR INVASION; ANIMAL; CELL CULTURE; CELL MOTION; DEFICIENCY; GENETIC EPIGENESIS; GENETICS; HEK293 CELL LINE; KIDNEY TUMOR; MESODERM; METABOLISM; PATHOLOGY;

ANIMALS; CELL MOVEMENT; CELLS, CULTURED; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; FUMARATE HYDRATASE; FUMARATES; HEK293 CELLS; HUMANS; KIDNEY NEOPLASMS; MESODERM; MICE; MICRORNAS; TRANSCRIPTION FACTORS; TRANSCRIPTOME;

EID: 84989159124     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature20144     Document Type: Erratum

References (40)

1. Tomlinson, I. P. et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30, 406-410 (2002).
2. Schmidt, L. S. and Linehan, W. M. Hereditary leiomyomatosis and renal cell carcinoma. Int. J. Nephrol. Renovasc. Dis. 7, 253-260 (2014).
3. Yang, M., Soga, T., Pollard, P. J. and Adam, J. The emerging role of fumarate as an oncometabolite. Front. Oncol. 2, 85 (2012).
4. Laukka, T. et al. Fumarate and succinate regulate expression of hypoxiainducible genes via TET enzymes. J. Biol. Chem. 291, 4256-4265 (2016).
5. Xiao, M. et al. Inhibition of a -KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 26, 1326-1338 (2012).
6. De Craene, B. and Berx, G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 13, 97-110 (2013).
7. Frezza, C. et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 477, 225-228 (2011).
8. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
9. Puisieux, A., Brabletz, T. and Caramel, J. Oncogenic roles of EMT-inducing transcription factors. Nat. Cell Biol. 16, 488-494 (2014).
10. Yang, M.-H. et al. Direct regulation of TWIST by HIF-1a promotes metastasis. Nat. Cell Biol. 10, 295-305 (2008).
11. Isaacs, J. S. et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143-153 (2005).
12. Bertout, J. A., Patel, S. A. and Simon, M. C. The impact of O2 availability on human cancer. Nat. Rev. Cancer 8, 967-975 (2008).
13. Davalos, V. et al. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 31, 2062-2074 (2012).
14. Song, S. J. et al. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 154, 311-324 (2013).
15. Hu, X. et al. Tet and TDG mediate DNA demethylation essential for mesenchymal-to-epithelial transition in somatic cell reprogramming. Cell Stem Cell 14, 512-522 (2014).
16. Heinemann, B. et al. Inhibition of demethylases by GSK-J1/J4. Nature 514, E1-E2 (2014).
17. Karolchik, D. et al. The UCSC Genome Browser database: 2014 update. Nucleic Acids Res. 42, D764-D770 (2014).
18. Hagege, H. et al. Quantitative analysis of chromosome conformation capture assays (3C-qPCR). Nat. Protocols 2, 1722-1733 (2007).
19. MacKenzie, E. D. et al. Cell-permeating a -ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol. Cell. Biol. 27, 3282-3289 (2007).
20. Buchmaier, B. S. et al. Renal cells express different forms of vimentin: the independent expression alteration of these forms is important in cell resistance to osmotic stress and apoptosis. PLoS One 8, e68301 (2013).
21. Zheng, L. et al. Fumarate induces redox-dependent senescence by modifying glutathione metabolism. Nat. Commun. 6, 6001 (2015).
22. Sullivan, L. B. et al. The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling. Mol. Cell 51, 236-248 (2013).
23. Cardaci, S. et al. Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis. Nat. Cell Biol. 17, 1317-1326 (2015).
24. Letouze, E. et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 23, 739-752 (2013).
25. Ooi, A. et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 20, 511-523 (2011).
26. Linehan, W. M. et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N. Engl. J. Med. 374, 135-145 (2016).
27. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43-49 (2013).
28. Fang, Y. et al. Protein expression of ZEB2 in renal cell carcinoma and its prognostic significance in patient survival. PLoS One 8, e62558 (2013).
29. Fieuw, A. et al. Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas. Int. J. Cancer 130, 2599-2606 (2012).
30. Ashrafian, H. et al. Expression profiling in progressive stages of fumaratehydratase deficiency: the contribution of metabolic changes to tumorigenesis. Cancer Res. 70, 9153-9165 (2010).
31. Li, L. C. and Dahiya, R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 18, 1427-1431 (2002).
32. Piccinini, F., Kiss, A. and Horvath, P. CellTracker (not only) for dummies. Bioinformatics 32, 955-957 (2016).
33. Schmidt, D. et al. ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. Methods 48, 240-248 (2009).
34. Rajeeve, V., Vendrell, I., Wilkes, E., Torbett, N. and Cutillas, P. R. Cross-species proteomics reveals specific modulation of signaling in cancer and stromal cells by phosphoinositide 3-kinase (PI3K) inhibitors. Mol. Cell. Proteomics 13, 1457-1470 (2014).
35. Casado, P. et al. Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells. Sci. Signal. 6, rs6 (2013).
36. Casado, P. and Cutillas, P. R. A self-validating quantitative mass spectrometry method for assessing the accuracy of high-content phosphoproteomic experiments. Mol. Cell. Proteomics 10, M110003079 (2011).
37. Cutillas, P. R. and Vanhaesebroeck, B. Quantitative profile of five murine core proteomes using label-free functional proteomics. Mol. Cell. Proteomics 6, 1560-1573 (2007).
38. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
39. Taube, J. H. et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl Acad. Sci. USA 107, 15449-15454 (2010).
40. Law, C. W., Chen, Y., Shi, W. and Smyth, G. K. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).